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Abstract
Background—Composition and diversity of intestinal microbial communities (microbiota) are 
generally accepted as a risk factor for poor outcomes; however, we cannot yet use this information 
to prevent adverse outcomes.
Methods—Stool was collected from eight long-term acute care hospital (LTACH) patients 
experiencing diarrhea and two fecal microbiota transplant donors; 16S rDNA V1-V2 hypervariable 
regions were sequenced. Composition and diversity of each sample were described. Stool was also 
tested for Clostridium difficile, vancomycin-resistant enterococci (VRE), and carbapenem-
resistant Enterobacteriaceae. Associations between microbiota diversity and demographic and 
clinical characteristics, including antibiotic use, were analyzed.
Results—Antibiotic exposure and Charlson Comorbidity Index were inversely correlated with 
diversity (Spearman = −0.7). Two patients were positive for VRE; both had microbiomes 
dominated by Enterococcus faecium, accounting for 67–84% of their microbiome.
Discussion—Antibiotic exposure correlated with diversity; however, other environmental and 
host factors not easily obtainable in a clinical setting are also known to impact the microbiota. 
Therefore, direct measurement of microbiome disruption by sequencing, rather than reliance on 
surrogate markers, might be most predictive of adverse outcomes.
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Conclusions—If and when microbiome characterization becomes a standard diagnostic test, 
improving our understanding of microbiome dynamics will allow for interpretation of results to 
improve patient outcomes.
Introduction
In recent years, research on the collective genome of microbial communities, known as the 
microbiome, living in or on humans has accelerated.1,2 A healthy intestinal microbiota 
assists in digestion and metabolism, and protects against pathogen invasion and overgrowth 
of pathobionts, which are commensal bacteria that can intermittently reside as minor 
members of the microbiota and also can act as pathogens when that microbiota becomes 
disrupted.3 Loss of microbial diversity or protective species, and overgrowth or dominance 
by a single organism are characteristic of microbiome disruption.
From birth, environment and host factors impact a person’s microbiota. However, capturing 
a lifetime of exposures is not feasible. Microbiome disruption is generally accepted as a risk 
factor for poor outcomes, such as infection and, as recently suggested, sepsis.4 However, we 
cannot yet use microbiome status to predict or prevent poor outcomes. One way to translate 
increasing understanding of the microbiome to the field of infection control is via the 
development and use of ‘Microbiome Disruption Indices’ (MDIs) (Figure 1). Such indices 
could become standardized criteria for not only characterizing the status of a patient’s 
microbiome but also evaluating and communicating the disruptive potential of various drugs, 
including antibiotics. Applications for MDIs range from improving antibiotic stewardship, 
infection control, and clinical management of patients, to assigning a risk index to 
antibiotics and other microbiota disruptive drugs during the drug approval process.
Among the host and environmental factors that lead to microbiota shifts,5–8 antibiotic 
exposures cause dramatic disruptions, lasting six months or more.9 Not only do antibiotic-
induced disruptions lead to a loss of colonization resistance to MDROs, but once 
colonization does occur, further disruptions can lead to dominance (defined as a single 
MDRO constituting ≥30% of the microbiota), which is associated with the occurrence of 
invasive infection and increased transmission risk through skin and environmental 
contamination.10,11 MDROs, such as Clostridium difficile, vancomycin-resistant enterococci 
(VRE), and carbapenem-resistant Enterobacteriaceae (CRE), are major public health 
concerns in healthcare settings, where they are transmitted between patients and can 
colonize the lower intestine in more individuals than they infect.12,13
Long-term acute care hospital (LTACH) patients are a population with high antibiotic 
consumption,14 likely leading to severe intestinal microbiota disruption. In an effort to make 
a case for the potential impact of MDIs in improving infection control, we describe and 
compare the microbiomes from LTACH patients with prior antibiotic exposure, when 
individuals are most susceptible to MDRO colonization, to those of fecal microbiota 
transplant donors from a small pilot study, described below. We also examine associations 
between intestinal microbiome diversity, and clinical and demographic characteristics.
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METHODS
Study design and participants
The study was a cross-sectional pilot evaluation of the clinical characteristics and intestinal 
microbiome from a convenience sample of eight LTACH patients with new onset diarrhea 
and two healthy fecal microbiota transplant donors.15,16 The donors had no history of 
antibiotics in at least the previous 90 days and were not taking any other medications. 
Neither the LTACH patients nor the donors had histories of Crohn’s disease, ulcerative 
colitis, or other inflammatory bowel disease.
Patients were enrolled sequentially at first diarrheal episode during December 2013 through 
February 2014 when stool was being collected for C. difficile diagnostic PCR testing 
(GenExpert, Cepheid). Providers (S.L., J.M.) consented patients (or a family member for 
patients unable to consent) to have stool collected for microbiome analysis.
Data collected on each patient during retrospective chart review (A.C.) included 
demographics, proton pump inhibitor use, previous C. difficile infection, comorbidities, and 
antibiotic use in both the LTACH and acute care settings. Each antibiotic was classified by 
when it was administered in reference to the date of stool collection: day of or day before, 
during the seven days before, and during the 30 days before stool collection. Data were used 
to calculate cumulative antibiotic days17 and the number of days exposed to any (i.e., ≥ 1) 
antibiotic. Antibiotics were categorized into classes: carbapenems, cephalosporins (first-
generation), cephalosporins (third- and fourth-generation), beta-lactam/beta-lactamase 
inhibitor (BL/BLI) combinations, fluoroquinolones, glycopeptides (vancomycin), 
metronidazole, or other antibiotics. For vancomycin, route of administration was 
documented.
The Emory University Institutional Review Board (IRB) approved this study protocol. No 
incentives were provided for participation.
MDRO Colonization Status
In addition to C. difficile diagnostic PCR testing, patient stool was cultured for VRE using 
Spectra VRE chromogenic agar (Remel, Lenexa, KS) and screened for CRE using a 
selective medium containing ertapenem (http://www.cdc.gov/hai/pdfs/labSettings/
Klebsiella_or_Ecoli.pdf). At the time of collection, stool specimens were de-identified; 
linkage to the clinical specimen was known only to C.K.
Sample processing and next generation sequencing analyses
Because the majority of the microbiota cannot be cultured using current laboratory methods,
18
 next generation sequencing analysis to describe the bacteria present was performed on 
either residual stool (i.e., stool remaining after C. difficile diagnostic PCR testing) or stool 
collected within 7–10 days of C. difficile diagnostic PCR testing if insufficient residual stool 
was available. Stool was stored at 4°C and processed within 24 hours. DNA was extracted; 
the target 16S ribosomal gene hypervariable V1 and V2 regions were PCR amplified and 
PCR products were sequenced using an Illumina MiSeq instrument (Illumina, San Diego, 
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CA). Within each sample, any DNA sequences sharing ≥97% similarity were clustered into 
operational taxonomic units (OTUs) (equivalent to a bacterial species, genus, or family).19 
To assess within-sample microbial composition, or alpha diversity, we calculated values for 
Shannon Diversity Index9 and Observed Species, represented by the number of unique 
OTUs within a single sample. The Shannon Index accounts for both abundance and evenness 
to measure non-redundancy within a sample. To measure between-sample composition, we 
completed beta-diversity community analyses, using weighted UniFrac distance,20 which 
accounts for OTU abundances and phylogenetic distances. For additional details on sample 
processing, next generation sequencing, and sequence analyses, see Supplemental Methods.
Data analysis
For univariable analyses, relationships between demographic and clinical variables and 
alpha diversity were evaluated using nonparametric methods: Spearman’s correlation for 
continuous variables and Wilcoxon Rank Sum exact for categorical variables. All analyses 
were performed using SAS 9.3 (Cary, NC) or R statistical software (version 3.0.2).
RESULTS
Study design and participants
Summary demographic and clinical characteristics are in Table 1. Both donors were male, 
ages 29 and 30 years. Four of eight patients were male, and median age at stool collection 
was 66.5 (range: 50–75) years. At the time of stool collection, patients had been in the 
facility for a median of 3 (range: 0–52) days and were hospitalized in a short-stay acute care 
hospital a median 41.5 (range: 18–85) days before admission to the LTACH. All patients 
received antibiotics in the 30 days before stool collection. Patients received a median 34 
(range: 4–76) cumulative antibiotic days and spent a median of 17.5 (range: 3–30) days on 
any antibiotic in the 30 days before stool sample collection.
MDRO colonization status
Patient-07 had a positive C. difficile PCR diagnostic test. Two of eight patient stools were 
positive for VRE by culture (Patient-09, 10), and one was positive for CRE (Patient-09) 
(Figure 2).
Next generation sequencing
Family-level microbial community composition for each sample is depicted in Figure 2. 
Seven of the patient microbiomes examined were dominated (≥30%) by a single OTU. 
Patient-04 was dominated by Bacteroides fragilis (32%), two patients were dominated by 
Enterococcus faecium (Patient-09, 67%; Patient-10, 84%), and five were dominated by other 
OTUs: Patient-06, 88% Pseudomonas aeruginosa; Patient-07, 98% Alistipes finegoldii; 
Patient-08, 48% Faecalibacterium prausnitzi; Patient-11, 98% Lactobacillus OTUs (57% 
Lactobacillus salivarius, 41% Lactobacillus rhamnosus). No single OTU dominated the 
microbiome of Patient-05.
To assess internal validity of our findings, we compared next generation sequencing results 
and clinical microbiology results. C. difficile sequences (<1%) were identified in Patient-07 
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stool, who had a positive C. difficile diagnostic PCR. Patient-08 and Patient-09 stools 
contained OTU sequences matching C. difficile (2%, 9%, respectively), although C. difficile 
diagnostic PCR performed approximately one week before stool was collected for next 
generation sequencing was negative. No subsequent C. difficile infections were documented 
in these two patients. E. faecium and E. faecalis sequences were identified in both patient 
stools that were culture positive for VRE (Patient-09, 10). Because the genus or species was 
not identified during CRE screening, we could only confirm whether the clinical 
microbiology results matched the next generation sequencing results at the family-level. 
Sequences matching several members of the Enterobacteriaceae family were identified in the 
CRE-positive patient (Patient-09), including Escherichia coli, Serratia marcescens, and 
Salmonella enterica.
Microbiome Composition: Diversity
Median Shannon Index was 3.1 (range: 0.5–6.1) overall, 2.3 (range: 0.5–5.1) among patient 
samples, and 6.0 (range: 6.0–6.1) among donor samples (Table 1, Figure 2). Median 
Observed Species (OTU count) overall was 339.2 (range: 119.5–901.6), 242.55 (range: 
119.5–827.0) among patient samples, and 829.8 (range: 757.9–901.6) among donor samples.
When all individuals were included, the number of Observed Species was inversely 
correlated with cumulative antibiotic days in the previous 30 days (Spearman correlation 
coefficient = −0.8, P = 0.009), days exposed to antibiotics in the previous 30 days (Spearman 
= −0.7, P = 0.02), cumulative antibiotic days in the previous seven days (Spearman = −0.6, P 
= 0.05), days exposed to antibiotics in the previous seven days (Spearman = −0.6, P = 0.05), 
and Charlson Comorbidity Index Score (Spearman = −0.8, P = 0.008) (Table 2). Shannon 
Index correlated inversely with cumulative antibiotic days in the previous 30 days 
(Spearman = −0.8, P = 0.002), days exposed to antibiotics in the previous 30 days 
(Spearman = −0.8, P = 0.01), and Charlson Comorbidity Index Score (Spearman = −0.9, P = 
0.002).
Among patients only, alpha diversity measures only correlated with cumulative antibiotic 
days in the previous 30 days although not significant (Shannon Index: Spearman = −0.7, P = 
0.06; Observed Species: Spearman = −0.6, P = 0.08), and Charlson Comorbidity Index 
Score (Shannon Index: Spearman = −0.7, P = 0.05; Observed Species: Spearman = −0.7, P = 
0.08). Alpha diversity was significantly lower among patients who had received third or 
fourth-generation cephalosporins during the 30 days before stool collection (Shannon Index: 
0.68 versus 3.75; Wilcoxon, P = 0.04; Observed Species: 122.0 versus 404.8; Wilcoxon, P = 
0.04). The number of Observed Species was also lower among patients who had received 
carbapenems in the past 30 days (122.0 versus 404.8, P = 0.07) (Table 2).
Weighted UniFrac beta diversity analysis results are plotted in Figure 3. The VRE positive 
patients (LTACH-09, 10) were closest (weighted UniFrac distance=0.26), followed by 
LTACH-10, 11 (0.53), and the two healthy donors (0.65). Small distances indicates 
similarity between microbial communities from different individuals.
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Discussion
We describe intestinal microbial communities among LTACH patients with diarrhea, in an 
effort to highlight the potential impact of MDIs on infection control and prevention. In 
addition to Charlson Comorbidity Index Score, we found that antibiotic exposure in the 
previous month was inversely correlated with diversity measures, further strengthening the 
conclusion that cumulative antibiotic exposure is a major driver of microbiome disruption. 
Disruption could result in poor future outcomes, including infections and transmission 
(Figure 1). Additionally, although we did not assess outcomes, the significant inverse 
correlation with the Charlson Comorbidity Index further supports our hypothesis that 
microbiota characterization might also predict poor future outcomes. Before microbiome 
characterization or MDIs can become a standard diagnostic test that drives improved patient 
outcomes, our understanding of the dynamics of microbiome composition needs to be 
advanced.
The spectrum of microbiome composition among patients ranged from resembling healthy 
donors, such as in Patient-04 which had a weighted UniFrac distance of 0.81 from the 
healthy donors), to partial loss of Bacteroidetes (Patient-05) in a patient receiving only 
inhaled tobramycin, to dominance by E. faecium (Patient-09) and virtual mono-dominance 
by E. faecium (Patient-10), Lactobacillus (Patient-11), or Rikenellaceae (Patient-07) 
(Figures 2, 3). Although dominance by Enterococcus in LTACH patients has not been 
previously described, dominance by Enterococcus has been reported in patients undergoing 
allogeneic hematopoietic stem cell transplantation and is associated with increased risk for 
bacteremia.10
The impact of mono-dominance by other bacteria on morbidity and mortality is not well-
understood and might vary by patient population. For example, Lactobacillus species are 
typically thought of as a non-dominant part of the commensal microbiome, including along 
the digestive tract; however, we found L. rhamnosus and L. salivarius dominated the 
microbiome of Patient-11. Lactobacillus are frequently resistant to vancomycin (10%−27% 
susceptible),21 and Patient-11 received oral and intravenous vancomycin before stool 
collection, which might have enabled overgrowth of Lactobacillus. Intravenous vancomycin 
has been identified as an independent risk factor for C. difficile infection,22 demonstrating 
its disruptive potential. Although Lactobacillus can cause infection in sterile sites among 
highly debilitated patients, they cause infection much less frequently than well-recognized 
pathobiont MDROs, such as VRE. Consequently, it will be important to gain increased 
understanding of how dominance by low virulence commensals, such as Lactobacillus, 
impact outcomes. The genus or species dominating the intestine, and the metabolic functions 
performed by these dominating bacteria (e.g., Enterococcus versus Bacteroides) may be 
impacting overall health of the host and could be translated into a MDI. Determining how 
often dominance by different bacteria leads to infection in specific patient populations will 
help us better elucidate the impact of mono-dominance by bacteria not generally considered 
pathogens.
Recent exposures to third- or fourth-generation cephalosporins and carbapenems were 
common in microbiomes that tended towards lower diversity. This is biologically plausible 
Halpin et al. Page 6
Am J Infect Control. Author manuscript; available in PMC 2019 May 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
for carbapenems, which have broad spectrum and distribution in tissues and feces,23 as well 
as for intravenous ceftriaxone, which is excreted in stool at high concentrations.24 Receipt of 
third- and fourth-generation cephalosporins has also been identified as an important and 
widespread risk factor for C. difficile-associated diarrhea.25 The inverse correlation between 
antibiotic exposures and microbiome disruption reiterates the value and importance of 
implementing and maintaining an antimicrobial stewardship program to improve prescribing 
practices, in particular optimizing duration.
This study had several limitations, including that the design was a pilot study in a 
convenience sample, which prevents us from drawing major, generalizable conclusions, 
establishing whether C. difficile or MDRO colonization or infection preceded disruption, or 
performing multivariable analyses controlling for factors previously identified as impacting 
microbial diversity. However, the intent of the study was to allow us to present the concept 
of the importance of development of microbiome disruption indices and their potential 
implications on infection control and prevention efforts. In addition, by targeting patients 
with diarrhea, we selected for individuals likely to have more disrupted intestinal microbial 
communities than asymptomatic patients. Donors were younger than patients. Compared to 
younger adults, intestinal microbial communities vary widely in older populations26,27; 
however, this may be due to increasing exposure to antibiotics over time..
Previous research showed a relationship between presence of specific obligate anaerobes, 
Barnesiella species and C. scindens, and absence of VRE and C. difficile, respectively.28,29 
In our sample, only the healthy donors, as well as Patient-04 and Patient-08 had Barnesiella 
species (Figure 2). As predicted, these individuals simultaneously lacked any Enterococcus 
sequences in their intestinal microbiomes and may be protected from colonization if 
transmission were to occur. C. scindens was not identified in any of the microbiomes 
analyzed. In addition, Faecalibacterium prausnitzi, identified as an anti-inflammatory 
intestinal community member,30 was also found in both healthy donors and three LTACH 
patients.
Our cross-sectional pilot highlighted several potential MDIs beyond diversity metrics: 
relative absence of healthy components of the microbial flora, loss of keystone components 
that fill an ecologic niche and prevent colonization by a MDRO, and presence or dominance 
by microbial community components that are indicators of microbiome disruption. One 
example of the need for multiple MDIs, interpreted in context, is Donor-02, whose 
microbiome had a high proportion of Bacteroides vulgatus (33%), which previous research 
has suggested can be pro-inflammatory when present at levels higher than observed in the 
healthy intestinal microbiomes.31 However, this individual’s microbiome also had an alpha 
diversity score higher than any of the other dominated microbiomes (Figure 2) and contained 
sequences matching bacteria previously identified as protective and anti-inflammatory 
(Barnesiella species and F. prausnitzi, Figure 2), indicating that a single measure of the 
microbial composition is likely insufficient for determining risk for poor outcomes.
There are many host and environmental drivers of microbial composition, including some 
not easily captured or described, such as antibiotics received early in life, whether breastfed 
or not during infancy, mode of delivery at birth, diet, co-morbidity history, a history of 
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appendectomy or other gastrointestinal surgery, receipt of certain drugs (other than 
antibiotics), and the intestinal microbial composition of close contacts.32,33 Because the 
selection of MDRO genetic determinants within a bacterial species is a relatively rare event 
following genetic mutation, rearrangement, or translocation, the more common widespread 
effect of antibiotics on MDRO transmission is mediated via microbial community 
disruption.34 Even when compared to a reliable, comprehensive antibiotic exposure history 
dating back several years, MDIs are the more proximate and therefore comprehensive 
indicators of risk for not only infection, but also transmission. MDIs determined for patients 
at critical points throughout their course of care hold promise for guiding infection control 
and clinical management (Figure 1).
We anticipate that MDIs will someday be used to predict the degree and type of disruption 
that typically result from administration of a specific antibiotic (Figure 1: Footnote 1), as 
well as describe the risk status of a patient at a given point in time for subsequent 
colonization (Figure 1: Footnote 2), dominance (Figure 1: Footnote 3), transmission and 
infection (Figure 1: Footnote 4) by a MDRO. As microbiome analyses become fiscally 
feasible, interpretation of patients’ MDIs at admission or during care could help identify 
modifiable patient-, unit- or facility-level factors, including informing infection control 
measures, such as appropriate use of cohorting, antibiotic selection, and treatments to help 
patients with poor MDIs return to a more healthy state (e.g., fecal microbiota transplant).
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Figure 1. 
Causal Pathway from health to disease: Microbiome Disruption Indices (MDI)
1. Antibiotic MDI indicates the potential an antibiotic has for disrupting the intestinal 
microbiome
2. Disrupted microbiome status MDI characterizes the degree and type of disruption in the 
intestinal microbiome, as well as the susceptibility to colonization by a MDRO
3. MDRO colonization MDI indicates susceptibility to overgrowth and dominance by a 
MDRO
4. MDI characterizing overgrowth and dominance by a MDRO indicates susceptibility for 
infection with a MDRO, and the potential for transmission to others through skin/
environment contamination.
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Figure 2. 
OTUs identified in each intestinal microbiota were aggregated at the Family taxonomic level 
and those that constituted ≥1% of sequences in the dataset are plotted. Each color represents 
a different Family. Sequences present at <1% were grouped into “Others”. The bottom 
portion of the figure aligns the demographic and clinical data of each patient with their 
intestinal microbiota.
*Third and fourth generation cephalosporins only.
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Figure 3. 
Weighted UniFrac Beta diversity results. ‘D’ indicates a donor microbiome. ‘L’ indicates an 
LTACH patient microbiome.
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Table 1.
Characteristics of population and health status
Characteristic No. (%) of subjects No. (%) LTACH patients No. (%) Stool donors
Total 10 8 (80) 2 (20)
Median age at collection (range) 61.5 (29–75) 66.5 (50–75) 29.5 (29–30)
Gender
 Male 6 (60) 4 (50) 2 (100)
 Female 4 (40) 4 (50)
Proton pump inhibitor use 7 (70) 7 (87.5)
Acid reducer (H2 blocker) use 1 (10) 1 (12.5)
Steroid use 3 (30) 3 (37.5)
Feeding tube 8 (80) 8 (100)
Charlson Comorbidity Index Score
 0 2 (20) 0 (0) 2 (100)
 1–3 1 (10) 1 (12.5)
 4–6 4 (40) 4 (50)
 7–9 3 (30) 3 (37.5)
Number of observed species (OTUs), Median (range) 339.2 (119.5–901.6) 242.55 (119.5–827) 829.75 (757.9–901.6)
Shannon Diversity Index, Median (range) 3.08 (0.51–6.05) 2.3 (0.51–5.11) 5.99 (5.95–6.05)
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